Market Research Logo

Global Human Combination Vaccines Market 2017-2021

Global Human Combination Vaccines Market 2017-2021

About Human Combination Vaccines

A vaccine is made up of inactive, partially killed or dead viruses, to stimulate the immune system against the pathogenic virus and produce antibodies against it. Vaccines are injected or orally administered. Animal vaccines provide immunity to the animal body against pathogens. They are composed of attenuated or dead virus strains and can be administered via the intramuscular, intradermal, or oral route. Similarly, human vaccines are composed of inactivated or live attenuated virus particles and provide immunity to the human body against different pathogens and can be administered via the intramuscular, intradermal, oral, and subcutaneous route. The modern human vaccines are mostly composed of inactivated virus strains.

Technavio’s analysts forecast the global Human Combination Vaccines market to grow at a CAGR of 8.56% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global Human Combination Vaccines market for 2017-2021. To calculate the market size, the report considers the sales of both branded and generic versions of human combination vaccines.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Human Combination Vaccines Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • GlaxoSmithKline
  • Merck
  • Sanofi
Other prominent vendors
  • Daiichi Sankyo
  • Serum Institute of India
  • Takeda Pharmaceuticals
Market driver
  • Rise in cases of infectious diseases
  • For a full, detailed list, view our report
Market challenge
  • Requirement of cold chain logistics
  • For a full, detailed list, view our report
Market trend
  • Government-sponsored programs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Human Combination Vaccines Market 2017-2021

Technavio recognizes the following companies as the key players in the global human combination vaccines market: GlaxoSmithKline, Merck, and Sanofi.

Other Prominent Vendors in the market are: Daiichi Sankyo, Serum Institute of India, and Takeda Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is government-sponsored programs. In the past, various diseases have been eradicated globally due to continuous efforts by governments to develop effective combination vaccines and implement proper immunization programs. Vaccines are the cornerstone of the fight against various communicable diseases, which can be proven by the success of smallpox eradication, the drastic decrease in polio cases during the past few decades, the progress toward tetanus eradication, and the decrease in measles mortality rate. Despite such initiatives, infectious diseases remain one of the major causes of deaths worldwide.”

According to the report, one of the major drivers for this market is rise in cases of infectious diseases. Infectious diseases are one of the most common causes of illnesses and deaths worldwide. The presence of microbes and their ability to multiply and adapt to changing populations, environments, and technologies create an ongoing threat to public health. In developing countries, the influence of infectious diseases is often devastating, leading to decreased survival rates, particularly in the pediatric population, and impeding opportunities for economic growth and development.

Further, the report states that one of the major factors hindering the growth of this market is requirement of cold chain logistics. Cold chain logistics required for the storage of vaccines is a key challenge hindering the growth of global human combination vaccine markets, leading to lower acceptability among end-users. Combination vaccines should be stored in cold temperatures to retain their efficacy. They are likely to lose potency if the temperature drops below 2°C or shoots above 8°C. Care should be taken to avoid storing vaccines at freezing temperature as it will destroy vaccines, making them unfit for use. This loss of effectiveness is irreversible, leading to wastage of vaccines and related resources.



Companies Mentioned

GlaxoSmithKline, Merck, Sanofi, Daiichi Sankyo, Serum Institute of India, and Takeda Pharmaceuticals.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
  • Human combination vaccines: An overview
    • Need for development of combination vaccines
      • Table Advantages of human combination vaccines
      • Table Marketed human combination vaccines: Overview
    • Technical challenges faced during formulation of combination vaccines
    • Strategies for developing human combination vaccines
  • Key clinical trials
    • Table Pipeline molecule based on vendors
    • Table Product pipeline
    • Table Pipeline analysis of key clinical trials
  • Market landscape
    • Market overview
      • Table Global human combination vaccines market: Snapshot
    • Market size and forecast
      • Table Global human combination vaccines market 2016-2021 ($ millions)
      • Table Opportunity analysis in global human combination vaccines market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by vaccine type
    • Table Human combination vaccines market by vaccine type
    • Table Global human combination vaccine market share by vaccine type 2016
    • Human combination inactivated vaccines
      • Table Human combination inactivated vaccines market 2016-2021 ($ millions)
    • Human combination live attenuated vaccines
      • Table Human combination live attenuated vaccines market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Global human combination vaccines market by geography 2016 and 2021
    • Table Global human combination vaccines market revenue by geography 2016-2021 ($ millions)
    • Table Global human combination vaccines market share by geography 2016-2021
    • Human combination vaccines market in Americas
      • Table Market scenario in Americas
      • Table Human combination vaccines market in Americas 2016-2021 ($ millions)
    • Human combination vaccines market in EMEA
      • Table Market scenario in EMEA
      • Table Human combination vaccines market in EMEA 2016-2021 ($ millions)
    • Human combination vaccines market in APAC
      • Table Market scenario in APAC
      • Table Human combination vaccines market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Total number of children aged 0-5 years in US (millions)
      • Table Trends in population growth in developing regions
    • Market challenges
  • Market trends
    • Government-sponsored programs
    • Growing interest toward R&D of newer vaccines
    • More focus on emerging countries
    • Public-private initiatives
    • Threat of bioterrorism
    • Improvements in healthcare infrastructure
  • Vendor landscape
    • Competitive landscape
      • Table Competitive structure analysis of global human combination vaccines market 2016
  • Key vendor analysis
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Key highlights
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • Merck
      • Table Merck: Key highlights
      • Table Merck: Strength assessment
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
    • Sanofi
      • Table Sanofi: Key highlights
      • Table Sanofi: Strength assessment
      • Table Sanofi: Strategy assessment
      • Table Sanofi: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report